title: Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
authors.affiliation: School of Health and Population Sciences, University of Birmingham, Birmingham. N.Freemantle@bham.ac.uk
authors.forename: Nick
authors.initials: N
authors.lastname: Freemantle
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D017277:Drug Approval; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000600:supply & distribution*; D000077154:Rosiglitazone; D056737:Safety-Based Drug Withdrawals; D045162:Thiazolidinediones / Q000009:adverse effects / Q000600:supply & distribution*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone